Bimekizumab Tops Adalimumab for Plaque Psoriasis Bimekizumab Tops Adalimumab for Plaque Psoriasis

At week 16, 86.2% of those in the bimekizumab group had a PASI 90 response, compared with 47.2% in the adalimumab group.Medscape Medical News

Source: Medscape Dermatology Headlines - April 23, 2021 Category: Dermatology Tags: Dermatology News Source Type: news